Physician profile
Reed Michael Gioe
NPI 1043847684
$7,826.69
in general payments reported to CMS, 2019-2025
29 companies · $3,463 in 2025
The $3,463 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $482 · 2023: $1,848 · 2024: $2,033 · 2025: $3,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,021 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,020.68 |
| Education | $323.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $911.19 | 2023-2025 | Tremfya |
| Janssen Biotech, INC. | $875.99 | 2022-2025 | Tremfya, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $845.60 | 2023-2025 | Cabtreo, Siliq, Arazlo |
| Regeneron Healthcare Solutions, INC. | $802.52 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $661.43 | 2022-2025 | |
| Ucb, INC. | $650.96 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $387.81 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $322.63 | 2022-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.65 | 2023-2025 | Spevigo |
| Incyte Corporation | $258.92 | 2022-2025 | Opzelura |
| Regeneron Pharmaceuticals, INC. | $253.77 | 2024-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $252.39 | 2023-2025 | Zoryve |
| Genzyme Corporation | $190.31 | 2022-2025 | |
| Therakos LLC | $145.98 | 2025 | Uvadex, Cellex |
| Fresenius Kabi USA, LLC | $144.91 | 2023-2024 | Idacio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $144.31 | 2023 | Vtama |
| Pfizer INC. | $142.74 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $121.87 | 2023 | Rebyota |
| Mallinckrodt Hospital Products INC. | $62.03 | 2024-2025 | Acthar |
| Leo Pharma INC. | $61.92 | 2023-2025 | Adbry, Anzupgo |
| Amgen INC. | $43.77 | 2023-2024 | Otezla |
| Kyowa Kirin, INC. | $42.73 | 2022-2024 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $42.03 | 2022-2024 | |
| Revance Therapeutics, INC. | $36.91 | 2025 | Daxxify |
| Lilly USA, LLC | $34.21 | 2023 | Taltz, Olumiant |
| Blueprint Medicines Corporation | $28.46 | 2025 | Ayvakit |
| Sun Pharmaceutical Industries INC. | $26.83 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $19.07 | 2024 | Valchlor |
| Botanix Sb INC | $18.75 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Gioe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.